ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2550 |
|
953769-46-5 |
Sotuletinib (BLZ945) 98+% |
C20H22N4O3S | |
CL2375A |
|
923288-90-8 |
Nilotinib Hydrochloride Monohydrate;Nilotinib HCl Monohydrate 98+% |
C28H25ClF3N7O2 | |
CLA1359 |
|
1365287-97-3 |
Emibetuzumab (Anti-HGFR / c-Met) 95+% |
— | |
CLA1336 |
|
1243266-04-7 |
Tovetumab (Anti-PDGFRA / CD140a) 95+% |
— | |
CLA1318 |
|
1204390-13-5 |
Dusigitumab 95+% |
— | |
CLA1314 |
|
1310460-86-6 |
Modotuximab (Anti-ERBB1 / EGFR / HER1) 95+% |
— | |
CLA1310 |
|
1312797-14-0 |
Parsatuzumab (Anti-EGFL7) 95+% |
— | |
CLA1304 |
|
959963-46-3 |
Imgatuzumab (Anti-ERBB1 / EGFR / HER1) 95+% |
— | |
CLA1303 |
|
1310460-85-5 |
Futuximab 95+% |
— | |
CLA1300 |
|
1314238-96-4 |
Duligotuzumab 95+% |
— | |
CLA1295 |
|
1262787-83-6 |
Patritumab (Anti-ERBB3 / HER3) 95+% |
— | |
CLA1280 |
|
1174900-84-5 |
Ficlatuzumab (Anti-HGF / SF) 95+% |
— | |
CLA1270 |
|
1133766-06-9 |
Onartuzumab (Anti-HGFR / c-Met) 95+% |
— | |
CLA1269 |
|
1206681-39-1 |
Namilumab (Anti-CSF2 / GM-CSF) 95+% |
— | |
CLA1256 |
|
1024603-93-7 |
Olaratumab (Anti-PDGFRA / CD140a) 95+% |
— | |
CLA1251 |
|
1036734-93-6 |
Teprotumumab (Anti-IGF-1R / CD221) 95+% |
— | |
CLA1250 |
|
1085337-57-0 |
Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) 95+% |
— | |
CLA1248 |
|
1005389-60-5 |
Dalotuzumab (Anti-IGF1R / CD221) 95+% |
— | |
CLA1240 |
|
725735-28-4 |
Intetumumab 95+% |
— | |
CLA1225 |
|
872514-65-3 |
Rilotumumab (Anti-HGF / SF) 95+% |
— | |